Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Drop in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 93,000 shares, a decline of 17.6% from the June 15th total of 112,800 shares. Based on an average daily trading volume, of 60,000 shares, the short-interest ratio is presently 1.6 days. Approximately 0.6% of the shares of the company are short sold.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.16% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and set a $5.00 price target on shares of Aptose Biosciences in a report on Wednesday, April 3rd. StockNews.com began coverage on shares of Aptose Biosciences in a report on Tuesday. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Aptose Biosciences in a report on Friday, June 14th. Finally, Canaccord Genuity Group decreased their price objective on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Aptose Biosciences Stock Performance

APTO stock opened at $0.70 on Tuesday. The company’s 50 day moving average is $0.95 and its 200 day moving average is $1.48. Aptose Biosciences has a 1-year low of $0.67 and a 1-year high of $5.10.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. Research analysts forecast that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.